Ophthalmology

There were no SUSARS and no endophthalmitis observed among 29 patients treated in the study.

AAVB-081 is intended to address retinitis pigmentosa that results from Usher syndrome type 1B.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Scott Jeffers, PhD, the chief technology officer at GenSight Biologics, discussed using Verdot’s FlexiPro system to produce Lumevoq gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Atsena announced initial positive data from the LIGHTHOUSE study of ATSN-201 in May 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Participants are being dosed with OCU400 in the ongoing phase 3 liMeliGhT trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

At the selected phase 2 dose, 76% of patients were injection free, with maintained visual acuity and fluid control.

The chief technology officer at GenSight Biologics discussed using Verdot’s FlexiPro system to produce Lumevoq gene therapy.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The chief medical officer and head of translational research at Ring Therapeutics discussed research presented at ASGCT 2024.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The full 52-week analysis of the phase 2 LUNA trial are expected in the first half of 2025.

The gene therapy has continued to demonstrate efficacy in updated data from the phase 2 PRISM trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA announced its START Pilot Program in October 2023 with a similar goal.

RG6501/OpRegen was well-tolerated, with no serious treatment-related AEs reported in follow-up data from a phase 1/2 trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The clinical professor of neurology and pediatrics at Keck School of Medicine of USC also discussed current strategies with gene therapy administration.

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

The trial's primary endpoint is improvement on Luminance Dependent Navigation Assessment (LDNA).